Could starting immunotherapy earlier improve outcomes for High-Risk melanoma?

NCT ID NCT07680699

Recruiting now Knowledge-focused Sponsor: AC Camargo Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study observes patients with high-risk stage II melanoma to see if starting anti-PD-1 immunotherapy before surgery leads to better outcomes compared to the usual timing after surgery. Researchers will track when patients begin systemic therapy and compare results between the two groups. No treatments are assigned by the study; all decisions are made by the patient's own doctor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If early anti-PD-1 therapy proves beneficial, it could guide doctors on when to start treatment for high-risk melanoma.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS MELANOMA

Contacts and locations

Locations

AC Camargo Cancer Center
RECRUITING

São Paulo, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.